{"id":"W4410038451","doi":"10.1016/j.euo.2025.04.004","title":"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck; Pfizer; Merck Healthcare KGaA","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Avelumab; Javelin; Oncology; Toxicity; Internal medicine; Urology; Bladder cancer; Immunotherapy; Cancer; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002596117,0.0009304539,0.001915316,0.0002533853,0.0002604038,0.001139079,0.0007578246,0.0007505131,0.001671008],"category_scores_gemma":[0.002296565,0.0003330526,0.003116227,0.0004718879,0.0006109314,0.001091049,0.0005443126,0.0022944,0.000284143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007356188,"about_ca_system_score_gemma":0.000578281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001210888,"about_ca_topic_score_gemma":0.00244139,"domain_scores_codex":[0.9991036,0.0005094405,0.00004500293,0.0001508854,0.00006022317,0.0001307378],"domain_scores_gemma":[0.9984321,0.0004734171,0.0005124034,0.0002079972,0.00006133534,0.0003127281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.889764,0.001838183,0.04302898,0.001381431,0.01918727,0.0001349566,0.0001250091,0.002973018,0.004448539,0.0003667695,0.003114685,0.03363716],"study_design_scores_gemma":[0.4236882,0.1167403,0.4013207,0.0004498924,0.03643569,0.0006551563,0.0003739944,0.008234208,0.002989229,0.001602548,0.007286509,0.000223651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910706,0.006355663,0.0001847912,0.0002819723,0.00009192278,0.00005880236,0.001313151,0.0000229566,0.0006200984],"genre_scores_gemma":[0.9951966,0.00155023,0.0001922639,0.0002656283,0.0001024259,0.00008160672,0.001796748,0.00001092323,0.0008034808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002596117,"threshold_uncertainty_score":0.01372969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06087568181395224,"score_gpt":0.3749091265974353,"score_spread":0.3140334447834831,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}